Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.85 |
| ▸ | GBA1 | P04062 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.56 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71063 | 1.00 | FUCA1 (0.85) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL562632 | 1.00 | FUCA1 (0.85) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL20017877 | 1.00 | FUCA1 (0.85) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL5155562 | 1.00 | FUCA1 (0.85) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| Hydrochloric Acid SCHEMBL10840201 | 0.98 | FUCA1 (0.81) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL15599205 | 0.92 | FUCA1 (0.92) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL7637770 | 0.92 | FUCA1 (1.00) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL15599027 | 0.92 | FUCA1 (0.92) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL17181666 | 0.92 | FUCA1 (0.92) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 | |
| SCHEMBL15599028 | 0.92 | FUCA1 (0.92) | FUCA1GBA1SIGMAR1ALDH1A1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | claimed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | claimed |
| US-20180009841-A1 | METHOD FOR PREPARING NANOPRECIPITATES OF LOW MOLECULAR WEIGHT PEPTIDE OR PROTEIN | CARLINA TECHNOLOGIES (FR) | 2018-01-11 | — | — | US | claimed |
| EP-2990033-A1 | Process of nanoprecipitation of proteins and peptides with low molecular weight | Carlina Technologies (FR) | 2016-03-02 | — | — | EP | claimed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2025099451-A1 | NEW COMPOUNDS AND METHODS | Transition Bio Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| CN-119487009-A | Process for producing enantiomer (R) configuration of triazole derivative | 株式会社吴羽 | 2025-02-18 | — | — | CN | disclosed |
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-07-25 | — | — | US | disclosed |
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-07-25 | — | — | US | disclosed |
| CN-113493628-A | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-113122053-A | Quantum dot ink and preparation method of quantum dot film | TCL集团股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| WO-2021139794-A1 | CRYSTAL FORM OF PYRROLIDINYL UREA DERIVATIVE AND APPLICATION THEREOF | 漳州片仔癀药业股份有限公司 | 2021-07-15 | — | — | WO | disclosed |
| US-5585500-A | Method of producing optically active pyrrolidines with high enantiomeric purity | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | disclosed |
| EP-0692471-A1 | Process for the preparation of optically active 3-hydroxypyrrolidine derivatives with high optical purity | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0185882-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE 1-BENZYL-3,4-BIS-(DIPHENYLPHOSPHINO)-PYRROLIDINE | Degussa Aktiengesellschaft (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0151282-B1 | OPTICALLY ACTIVE 3,4-BIS-(DIPHENYLPHOSPHINO)-PYRROLIDINE, RHODIUM COMPLEXES CONTAINING THEM AS CHIRAL LIGANDS, AND THEIR USE | Degussa Aktiengesellschaft (DE) | 1988-09-07 | — | — | EP | disclosed |
| US-4668795-A | Process for the production of optically active 1-benzyl-3,4-bis-(diphenylphosphino)-pyrrolidine | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-05-26 | — | — | US | disclosed |
| US-4634775-A | HYDROGENATION CATALYSTS FOR ACYLAMINO-ACRYLIC ACIDS | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1987-01-06 | — | — | US | disclosed |
| EP-0185882-A1 | Process for preparing optically active 1-benzyl-3,4-bis-(diphenylphosphino)-pyrrolidine | Degussa Aktiengesellschaft (DE) | 1986-07-02 | — | — | EP | disclosed |
| EP-0151282-A1 | Optically active 3,4-bis-(diphenylphosphino)-pyrrolidine, rhodium complexes containing them as chiral ligands, and their use | Degussa Aktiengesellschaft (DE) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | NGF, LCK, RET | FUCA1 3455/4885GBA1 2626/4885SIGMAR1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.